Do patients with central sensitivity syndromes have poor subjective outcomes despite anatomical cure from pelvic organ prolapse surgery?

INTRODUCTION: Pelvic organ prolapse(POP) has an adverse impact on quality of life with lifetime risk of surgery varying from 11 to 20%. Conditions such as fibromyalgia (FMS), chronic fatigue syndrome (CFS/ME) and irritable bowel syndrome (IBS), collectively known as central sensitivity syndromes (CSS), may affect the outcome of POP surgery. The aim of this article is to compare the outcomes of vaginal POP surgery between women with and without CSS. METHOD: This was a prospective cohort study. The validated Central Sensitisation Inventory (CSI) was used to identify women with CSS. Subjective and objective outcomes were compared between the two groups using POP-SS, Expectation and satisfaction/"EGGS", pain scores and the POP quantification system (POP-Q). A non-parametric test was used for analysis. RESULT: Seventy-eight women were recruited. Complete data were available in 62 patients; 23 patients had evidence of CSS and 39 did not. Women with CSS had significantly higher pre- and post-operative POP-SS scores than those without (p < 0.0005, p = 0.004). Seventeen (73.9%) women with CSS compared to 38 (97.4%) women without CSS demonstrated improvement of a minimum 6 points on the POP-SS scale; however, this was not stastically significant. McGill's pain scores were higher in women with CSS both pre- and post-surgery. Ninety-five per cent of women without CSS achieved their goals and were satisfied with the surgery compared to 69.5% of women with CSS (p < 005). CONCLUSION: There is a less favourable outcome of POP surgery in women with CSS compared to those without in terms of persistence of symptoms, pain and overall satisfaction.

Variations in implementation of bladder training for overactive bladder: an online international survey.

We distributed an online questionnaire to 365 health care professionals specialising in urogynaecology, using the International Urogynaecology Association (IUGA) and British Society of Urogynecolgoy (BSUG) directories to investigate how the bladder training (BT) is provided in their units. We assessed the techniques provided, who provides them, and how these techniques are implemented and taught to the patients. Two hundred and thirteen (59%) completed responses have been received. 88% of the respondents felt that BT is an important and effective tool in treating overactive bladder. 50.7% indicated those physiotherapists are the health care practitioners responsible to deliver BT in their units. 88.3% of respondents use face-to-face consultation to deliver BT, 11% only use leaflets sent to patients. 87% use bladder diaries before implementing their BT. 26.4% use anti-muscarinic medications with BT from the start.IMPACT STATEMENTWhat is already known on this subject? Bladder training (BT) is a well-established behavioural therapy used to treat overactive bladder with comparable efficacy to pharmacotherapy with less side effects. It I recommended to be offered as first line therapy for at least 6 weeks. However, there is no clarity about the techniques and the methods used to deliver it.What do the results of the study add? The current study aimed to find out how the BT programme delivered to patients using an online questionnaire directed to a mixed group of medical urogynecology practitioners in different geographical regions. It showed that there is a wide variation in how the BT is delivered and lack of consistency in the techniques used and the duration recommended.What are the implications of these findings for clinical practice and/or further research? Future well-designed research is needed to look at the best ways to give BT instructions, the frequency of supervision of patients who use BT, the appropriate time length of the BT programme, and the best strategies to control urgency.

The proportion of women with central sensitivity syndrome in gynecology outpatient clinics (GOPDs).

INTRODUCTION AND HYPOTHESIS: Patients in gynecology outpatient clinics (GOPDs) may present with symptoms that do not correlate well with the observed pathology and are usually labelled as having a functional disorder or medically unexplained symptoms (MUS). Underlying central sensitivity syndrome (CSS) with central sensitization (CS) as a potential mechanism may be responsible for some of their symptoms. The aim of this study is to identify the proportion of women with central sensitivity syndrome attending GOPDs. METHODS: This was a prospective study. All women attending a GOPD included in the study were asked to complete a validated Central Sensitization Inventory (CSI). The responses were graded on a Likert scale from 0 (never) to 4 (always). The total score ranges from 0 to 100. For screening purposes, a single CSI cutoff score of 40 was used to identify the group of women who may have central sensitization syndrome. RESULTS: Three hundred twenty-six women participated in the study. Overall, 123 (37%) women achieved a score above 40. This could be interpreted as these patients having increased risk of underlying central sensitization. Of these, 43 had a previously confirmed diagnosis of migraine, 55 (44%) depression, 39 (31.7%) anxiety, 11 fibromyalgia (FM), 34 irritable bowel syndrome (IBS) and 16 chronic fatigue syndrome (CFS/ME). CONCLUSIONS: Managing patients and their expectations in gynecological outpatient departments when symptoms are inconsistent with observable pathological findings is challenging. This is further complicated when patients have a concomitant central sensitivity syndrome, which can also influence the surgical outcome. Identifying these patients is a key factor for appropriate management.

Neuromodulation for Pelvic and Urogenital Pain.

Chronic pain affecting the pelvic and urogenital area is a major clinical problem with heterogeneous etiology, affecting both male and female patients and severely compromising quality of life. In cases where pharmacotherapy is ineffective, neuromodulation is proving to be a potential avenue to enhance analgesic outcomes. However, clinicians who frequently see patients with pelvic pain are not traditionally trained in a range of neuromodulation techniques. The aim of this overview is to describe major types of pelvic and urogenital pain syndromes and the neuromodulation approaches that have been trialed, including peripheral nerve stimulation, dorsal root ganglion stimulation, spinal cord stimulation, and brain stimulation techniques. Our conclusion is that neuromodulation, particularly of the peripheral nerves, may provide benefits for patients with pelvic pain. However, larger prospective randomized studies with carefully selected patient groups are required to establish efficacy and determine which patients are likely to achieve the best outcomes.